ID

46128

Description

Principal Investigator: Gloria Pryhuber, University of Rochester Rochester, Rochester, NY, USA MeSH: Infant, Premature,Infant, Newborn,Premature Birth,Term Birth,Microbiota,Gastrointestinal Microbiome,T-Lymphocytes,Bronchopulmonary Dysplasia,Respiratory Tract Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001347 *Public health importance*: Babies born preterm, approximately 1 out of every 9 live births in the United States, have significant respiratory morbidity over the first two years of life, exacerbated by respiratory viral infections. Many (50%) return to pediatricians, emergency rooms and pulmonologists with symptoms of respiratory dysfunction (SRD): intermittent or chronic wheezing, poor growth and an excess of upper and lower respiratory tract infections (LRTI). SRD correlate inversely with gestational age and weight at birth and is more common in those with chronic lung disease of prematurity, yet its incidence and severity varies widely among both the prematurely born and those born at term. There is evidence from clinical studies and animal models that risks of LRTI and recurrent wheezing is influenced by gut and respiratory flora and by T cell responses to infection. Information gained from this study will be used to identify characteristics, risk factors and potential mechanisms for early and persistent lung disease in children born at term and born preterm. This Clinical Research Study will investigate the relationships between sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity in preterm and full term infants. We hypothesize that the timing and acquisition of specific viral infections and bacterial species are directly related to respiratory morbidity in the first year of life as defined by SRD and by measures of pulmonary function. We hypothesize that cellular and molecular immuno-maturity are altered due to factors presented by premature birth in such a way as to promote chronic inflammatory and cytotoxic damage to the lung, with subsequent enhanced, damaging responses to infectious agents and environmental irritants. Our preliminary studies demonstrate both feasibility and expertise in mutiparameter immunophenotyping of small volume peripheral blood samples obtained from premature infants including gene expression arrays of flow cytometry sorted cells. We will use new technologies for known viral identification, as well as high-throughput metagenome sequencing of RNA and DNA virus like particles (VLP) to be used for viral discovery in infant respiratory sample and use of high-throughput pyrosequencing (454T) of bacterial 16S rRNA to determine shifts in bacterial community structure, occurring in pre-term (PT) as compared to full term (FT) infants, over the first year of life. Finally, we present statistical approaches to stratify disease risk predictors using multivariate logistic regression modeling approaches. We propose to evaluate T cell phenotypic and functional profiles relative to viral and predominant bacterial exposures according to highly complementary, but independent, Specific Objectives. *Objective 1*: To determine if viral respiratory infections and patterns of respiratory and gut bacterial community structure (microbiome) in prematurely born babies predict the rate and degree of immunologic maturation, and pulmonary dysfunction, measured from birth to 36 weeks corrected gestational age (CGA). *Objective 2*: To determine the relationship between respiratory viral infections and disease severity up to one year CGA, and the lymphocyte (Lc) phenotypes documented at term gestation (birth for term infants and 36 wks/NICU discharge in preterm infants) and at one year CGA. Three secondary outcomes of this objective will be to a) relate the quantity, type and severity of viral infections with pulmonary function at one and three years of life, b) relate the viral community structure to severity of viral infections and c) to seek evidence of modulation of viral susceptibility by bacterial respiratory and gut community structure (microbiome). The relationship of colonization with known and non-identified bacterial species in both the respiratory tract and the gut will be evaluated. Flow cytometry data corresponding to this study can be found within Immport study SDY1302. Positive and negative controls for microbiome samples are uploaded under SRA bioproject PRJNA474485. Microbiome samples corresponding to PRISM2 are distinguished from PRISM1 via "_PRISM2" appended to the sample name. Within the positive and negative controls, PRISM1 controls are uploaded as bam files and PRISM2 controls are uploaded as paired fastq. Samples ending in -08 correspond to TLDA qPCR results for a given sample. There is a column for each pathogen tested and a column to indicate where that pathogen was bacteria or virus.

Link

dbGaP study id = phs001347

Keywords

  1. 11/11/24 11/11/24 - Dr. Christian Niklas
Copyright Holder

Gloria Pryhuber, University of Rochester Rochester, Rochester, NY, USA

Uploaded on

November 11, 2024

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


No comments

In order to download data models you must be logged in. Please log in or register for free.

dbGaP phs001347 Prematurity, Respiratory Outcomes, Immune System, and Microbiome Study (PRISM)

Eligibility Criteria

  1. StudyEvent: Prematurity Respiratory Outcomes Immune System and Microbiome Study
    1. Eligibility Criteria
    2. The subject consent file includes subject IDs, consent information, subject aliases, and study ID.
    3. This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
    4. This subject phenotype table contains subject IDs, cohort, sex, ethnic, race, gestational ages at birth and discharge, birth mode, bronchopulmonary dysplasia status, persistent repiratory disease after one year, oxygen AUC (Area Under the ROC curve) at 7 and 14 days, days on 7 variables (oxygen, mechanical ventilation, high frequency ventilation, cpap, nasal cannula gt 1 lmp, any respiratory support, and nasal cannula), maximum mean airway pressure, last PMA and DOL on ETT for GT 2 days in a row, exposure to furry animals in the home, asthma, allergies and eczema within siblings, BMI of the mother at the time of delivery, chlorioamnionitis, season of birth, derived respiratory severity score, oxygen AUC for first 14 days of life, and difference between FIO2 weeks 1 and 2.
    5. This sample attributes table contains sample IDs, visit, postmenstrual ages at time of nsasal or rectal swab sampling, day of life of the nasal or rectal tests, body site, read counts, analyte type, tumor status, histological type, region of bacteria being sequenced, presence of bacteria or virus (Adenovirus, Bocavirus, Bordetella pertussis, Coronavirus 1-4, Chlamydophila pneumoniae, Enterobacteriaceae, Flu A, Flu B, Haemophilus influenzae, Human metapneumovirus, Moraxella, Mycoplasma hominis, Mycoplasma pneumoniae, parechovirus, PIV 1-3, Rhinovirus, RSV, Streptococcus pneumoniae, and Ureaplasma) within the sample, corresponding bacteria or virus classification, hospital admissions, due to wheezing or breathing problems, admitted to intensive care, admissions due to RSV, sick visits, sick visits due to wheezing or breathing problems or wheezing unknown, has baby chest sounded wheezy or whistling, occurred with or without colds, chest wheezy during daytime or nighttime, diagnosed with wheezing by doctor, cough without cold, coughing during daytime or nighttime, number of colds, breathing and heart rate monitor, oxygen therapy, CPAP or BIPAP, ventilator, trach or breathing tube, feeding tube in nose or stomach, other equipment used, is baby receiving breast milk, is baby receiving breast milk exclusively, did baby receive breast milk since last visit, for how many months did baby receive breast milk for more than half of feedings, does baby eat any non-milk foods, and what non-milk foods does baby eat.
Inclusion criteria
Description

Inclusion criteria

Alias
UMLS CUI [1,1]
C1512693
Signed Informed Consent from parent(s) or legal guardian(s)
Description

Elig.phs001347.v3.p2.2

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0030551
UMLS CUI [1,3]
C1274041
Preterm infants born at gestational age 23 0/7 to 35 6/7 weeks
Description

Elig.phs001347.v3.p2.3

Data type

boolean

Alias
UMLS CUI [1,1]
C4048294
UMLS CUI [1,2]
C0017504
Preterm infants admitted to the URMC NICU or Normal Newborn Nursery
Description

Elig.phs001347.v3.p2.4

Data type

boolean

Alias
UMLS CUI [1,1]
C4048294
UMLS CUI [1,2]
C0000872
UMLS CUI [1,3]
C0809949
UMLS CUI [1,4]
C0021709
UMLS CUI [2,1]
C4048294
UMLS CUI [2,2]
C0000872
UMLS CUI [2,3]
C0809949
UMLS CUI [2,4]
C1960106
Infants less than or equal to 7 days old
Description

Elig.phs001347.v3.p2.5

Data type

boolean

Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C0021270
UMLS CUI [1,3]
C0439090
Attending physician agreement
Description

Elig.phs001347.v3.p2.6

Data type

boolean

Alias
UMLS CUI [1,1]
C1320929
UMLS CUI [1,2]
C0680240
Healthy term infants 37 0/7 to 41 6/7 weeks gestation
Description

Elig.phs001347.v3.p2.7

Data type

boolean

Alias
UMLS CUI [1,1]
C3898900
UMLS CUI [1,2]
C0021270
UMLS CUI [1,3]
C0017504
Recruited prior to delivery, or from the birthing centers and labor and delivery floor
Description

Elig.phs001347.v3.p2.8

Data type

boolean

Alias
UMLS CUI [1,1]
C0242800
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C2053594
UMLS CUI [2,1]
C0242800
UMLS CUI [2,2]
C3887776
UMLS CUI [3,1]
C0242800
UMLS CUI [3,2]
C0085142
Infants less than or equal to 7 days old
Description

Elig.phs001347.v3.p2.9

Data type

boolean

Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C0021270
UMLS CUI [1,3]
C0439090
Signed Informed Consent from parent(s) or legal guardian(s)
Description

Elig.phs001347.v3.p2.10

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0030551
UMLS CUI [1,3]
C1274041
Exclusion criteria
Description

Exclusion criteria

Alias
UMLS CUI [1,1]
C0680251
Considered to be non-viable (decision by clinical care team to limit life-saving therapies)
Description

Elig.phs001347.v3.p2.11

Data type

boolean

Alias
UMLS CUI [1,1]
C0679006
UMLS CUI [1,2]
C0086390
UMLS CUI [1,3]
C0439801
UMLS CUI [1,4]
C0199171
UMLS CUI [2,1]
C5556942
Known congenital heart disease, not including patent ductus arteriosus (PDA), hemodynamically insignificant ventricular septal defect (VSD) or atrial septal defect (ASD)
Description

Elig.phs001347.v3.p2.12

Data type

boolean

Alias
UMLS CUI [1,1]
C0018798
UMLS CUI [1,2]
C1705847
UMLS CUI [1,3]
C0013274
UMLS CUI [1,4]
C0578150
UMLS CUI [1,5]
C0018818
UMLS CUI [1,6]
C0018817
Known structural abnormalities of the upper airway, lungs, or chest wall
Description

Elig.phs001347.v3.p2.13

Data type

boolean

Alias
UMLS CUI [1,1]
C0678594
UMLS CUI [1,2]
C1704258
UMLS CUI [1,3]
C0458578
UMLS CUI [1,4]
C0024109
UMLS CUI [1,5]
C0205076
Known other congenital malformations or syndromes that adversely affect life expectancy or cardiopulmonary development (i.e., neuromuscular disease, trisomy 21).
Description

Elig.phs001347.v3.p2.14

Data type

boolean

Alias
UMLS CUI [1,1]
C0000768
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0023671
UMLS CUI [2,1]
C0000768
UMLS CUI [2,2]
C0553534
UMLS CUI [2,3]
C0424605
Known to be born to women who are human immunodeficiency virus (HIV) positive (HIV testing is not required prior to study entry but is available for most mothers-to-be and is performed on all newborns in NY state).
Description

Elig.phs001347.v3.p2.15

Data type

boolean

Alias
UMLS CUI [1,1]
C0026591
UMLS CUI [1,2]
C0019699
Known congenital or acquired immune deficiency
Description

Elig.phs001347.v3.p2.16

Data type

boolean

Alias
UMLS CUI [1,1]
C1855771
UMLS CUI [1,2]
C1744681
UMLS CUI [2,1]
C1855771
UMLS CUI [2,2]
C0439661
Family is unlikely to be available for long-term follow-up.
Description

Elig.phs001347.v3.p2.17

Data type

boolean

Alias
UMLS CUI [1,1]
C0015576
UMLS CUI [1,2]
C0750558
UMLS CUI [1,3]
C1517942
No legal guardian who speaks and reads English.
Description

Elig.phs001347.v3.p2.18

Data type

boolean

Alias
UMLS CUI [1,1]
C1298908
UMLS CUI [1,2]
C0023226
UMLS CUI [1,3]
C0564215
UMLS CUI [1,4]
C0586740
UMLS CUI [1,5]
C0376245
Specifically for the term Infants, as healthy infants, no *NICU* admission prior to consent.
Description

Elig.phs001347.v3.p2.19

Data type

boolean

Alias
UMLS CUI [1,1]
C2348235
UMLS CUI [1,2]
C3898900
UMLS CUI [1,3]
C0021270
UMLS CUI [1,4]
C1298908
UMLS CUI [1,5]
C0021709
UMLS CUI [1,6]
C0332152
UMLS CUI [1,7]
C1511481
Any infant with a diagnosis of hypertension, hyperthyroidism, seizures, arrhythmias, or sensitivity to sympathomimetic amines will be excluded from the BDR assessment.
Description

Elig.phs001347.v3.p2.20

Data type

boolean

Alias
UMLS CUI [1,1]
C3166112
UMLS CUI [1,2]
C2828389
UMLS CUI [1,3]
C0020538
UMLS CUI [1,4]
C0020550
UMLS CUI [1,5]
C0036572
UMLS CUI [1,6]
C0003811
UMLS CUI [1,7]
C0020517
UMLS CUI [1,8]
C0002509
Any infant with hypersensitivity to any of components of albuterol sulfate will be excluded from the BDR assessment. An infant or child with such history may remain eligible for the remainder of the study if they qualify by other inclusion and exclusion criteria.
Description

Elig.phs001347.v3.p2.21

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0543495
UMLS CUI [1,3]
C2828389
UMLS CUI [1,4]
C3166112
UMLS CUI [2,1]
C1302261
UMLS CUI [2,2]
C0020517
UMLS CUI [2,3]
C0262926

Similar models

Eligibility Criteria

  1. StudyEvent: Prematurity Respiratory Outcomes Immune System and Microbiome Study
    1. Eligibility Criteria
    2. The subject consent file includes subject IDs, consent information, subject aliases, and study ID.
    3. This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
    4. This subject phenotype table contains subject IDs, cohort, sex, ethnic, race, gestational ages at birth and discharge, birth mode, bronchopulmonary dysplasia status, persistent repiratory disease after one year, oxygen AUC (Area Under the ROC curve) at 7 and 14 days, days on 7 variables (oxygen, mechanical ventilation, high frequency ventilation, cpap, nasal cannula gt 1 lmp, any respiratory support, and nasal cannula), maximum mean airway pressure, last PMA and DOL on ETT for GT 2 days in a row, exposure to furry animals in the home, asthma, allergies and eczema within siblings, BMI of the mother at the time of delivery, chlorioamnionitis, season of birth, derived respiratory severity score, oxygen AUC for first 14 days of life, and difference between FIO2 weeks 1 and 2.
    5. This sample attributes table contains sample IDs, visit, postmenstrual ages at time of nsasal or rectal swab sampling, day of life of the nasal or rectal tests, body site, read counts, analyte type, tumor status, histological type, region of bacteria being sequenced, presence of bacteria or virus (Adenovirus, Bocavirus, Bordetella pertussis, Coronavirus 1-4, Chlamydophila pneumoniae, Enterobacteriaceae, Flu A, Flu B, Haemophilus influenzae, Human metapneumovirus, Moraxella, Mycoplasma hominis, Mycoplasma pneumoniae, parechovirus, PIV 1-3, Rhinovirus, RSV, Streptococcus pneumoniae, and Ureaplasma) within the sample, corresponding bacteria or virus classification, hospital admissions, due to wheezing or breathing problems, admitted to intensive care, admissions due to RSV, sick visits, sick visits due to wheezing or breathing problems or wheezing unknown, has baby chest sounded wheezy or whistling, occurred with or without colds, chest wheezy during daytime or nighttime, diagnosed with wheezing by doctor, cough without cold, coughing during daytime or nighttime, number of colds, breathing and heart rate monitor, oxygen therapy, CPAP or BIPAP, ventilator, trach or breathing tube, feeding tube in nose or stomach, other equipment used, is baby receiving breast milk, is baby receiving breast milk exclusively, did baby receive breast milk since last visit, for how many months did baby receive breast milk for more than half of feedings, does baby eat any non-milk foods, and what non-milk foods does baby eat.
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI [1,1])
Elig.phs001347.v3.p2.2
Item
Signed Informed Consent from parent(s) or legal guardian(s)
boolean
C0021430 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C1274041 (UMLS CUI [1,3])
Elig.phs001347.v3.p2.3
Item
Preterm infants born at gestational age 23 0/7 to 35 6/7 weeks
boolean
C4048294 (UMLS CUI [1,1])
C0017504 (UMLS CUI [1,2])
Elig.phs001347.v3.p2.4
Item
Preterm infants admitted to the URMC NICU or Normal Newborn Nursery
boolean
C4048294 (UMLS CUI [1,1])
C0000872 (UMLS CUI [1,2])
C0809949 (UMLS CUI [1,3])
C0021709 (UMLS CUI [1,4])
C4048294 (UMLS CUI [2,1])
C0000872 (UMLS CUI [2,2])
C0809949 (UMLS CUI [2,3])
C1960106 (UMLS CUI [2,4])
Elig.phs001347.v3.p2.5
Item
Infants less than or equal to 7 days old
boolean
C0001779 (UMLS CUI [1,1])
C0021270 (UMLS CUI [1,2])
C0439090 (UMLS CUI [1,3])
Elig.phs001347.v3.p2.6
Item
Attending physician agreement
boolean
C1320929 (UMLS CUI [1,1])
C0680240 (UMLS CUI [1,2])
Elig.phs001347.v3.p2.7
Item
Healthy term infants 37 0/7 to 41 6/7 weeks gestation
boolean
C3898900 (UMLS CUI [1,1])
C0021270 (UMLS CUI [1,2])
C0017504 (UMLS CUI [1,3])
Elig.phs001347.v3.p2.8
Item
Recruited prior to delivery, or from the birthing centers and labor and delivery floor
boolean
C0242800 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C2053594 (UMLS CUI [1,3])
C0242800 (UMLS CUI [2,1])
C3887776 (UMLS CUI [2,2])
C0242800 (UMLS CUI [3,1])
C0085142 (UMLS CUI [3,2])
Elig.phs001347.v3.p2.9
Item
Infants less than or equal to 7 days old
boolean
C0001779 (UMLS CUI [1,1])
C0021270 (UMLS CUI [1,2])
C0439090 (UMLS CUI [1,3])
Elig.phs001347.v3.p2.10
Item
Signed Informed Consent from parent(s) or legal guardian(s)
boolean
C0021430 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C1274041 (UMLS CUI [1,3])
Item Group
Exclusion criteria
C0680251 (UMLS CUI [1,1])
Elig.phs001347.v3.p2.11
Item
Considered to be non-viable (decision by clinical care team to limit life-saving therapies)
boolean
C0679006 (UMLS CUI [1,1])
C0086390 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C0199171 (UMLS CUI [1,4])
C5556942 (UMLS CUI [2,1])
Elig.phs001347.v3.p2.12
Item
Known congenital heart disease, not including patent ductus arteriosus (PDA), hemodynamically insignificant ventricular septal defect (VSD) or atrial septal defect (ASD)
boolean
C0018798 (UMLS CUI [1,1])
C1705847 (UMLS CUI [1,2])
C0013274 (UMLS CUI [1,3])
C0578150 (UMLS CUI [1,4])
C0018818 (UMLS CUI [1,5])
C0018817 (UMLS CUI [1,6])
Elig.phs001347.v3.p2.13
Item
Known structural abnormalities of the upper airway, lungs, or chest wall
boolean
C0678594 (UMLS CUI [1,1])
C1704258 (UMLS CUI [1,2])
C0458578 (UMLS CUI [1,3])
C0024109 (UMLS CUI [1,4])
C0205076 (UMLS CUI [1,5])
Elig.phs001347.v3.p2.14
Item
Known other congenital malformations or syndromes that adversely affect life expectancy or cardiopulmonary development (i.e., neuromuscular disease, trisomy 21).
boolean
C0000768 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0023671 (UMLS CUI [1,3])
C0000768 (UMLS CUI [2,1])
C0553534 (UMLS CUI [2,2])
C0424605 (UMLS CUI [2,3])
Elig.phs001347.v3.p2.15
Item
Known to be born to women who are human immunodeficiency virus (HIV) positive (HIV testing is not required prior to study entry but is available for most mothers-to-be and is performed on all newborns in NY state).
boolean
C0026591 (UMLS CUI [1,1])
C0019699 (UMLS CUI [1,2])
Elig.phs001347.v3.p2.16
Item
Known congenital or acquired immune deficiency
boolean
C1855771 (UMLS CUI [1,1])
C1744681 (UMLS CUI [1,2])
C1855771 (UMLS CUI [2,1])
C0439661 (UMLS CUI [2,2])
Elig.phs001347.v3.p2.17
Item
Family is unlikely to be available for long-term follow-up.
boolean
C0015576 (UMLS CUI [1,1])
C0750558 (UMLS CUI [1,2])
C1517942 (UMLS CUI [1,3])
Elig.phs001347.v3.p2.18
Item
No legal guardian who speaks and reads English.
boolean
C1298908 (UMLS CUI [1,1])
C0023226 (UMLS CUI [1,2])
C0564215 (UMLS CUI [1,3])
C0586740 (UMLS CUI [1,4])
C0376245 (UMLS CUI [1,5])
Elig.phs001347.v3.p2.19
Item
Specifically for the term Infants, as healthy infants, no *NICU* admission prior to consent.
boolean
C2348235 (UMLS CUI [1,1])
C3898900 (UMLS CUI [1,2])
C0021270 (UMLS CUI [1,3])
C1298908 (UMLS CUI [1,4])
C0021709 (UMLS CUI [1,5])
C0332152 (UMLS CUI [1,6])
C1511481 (UMLS CUI [1,7])
Elig.phs001347.v3.p2.20
Item
Any infant with a diagnosis of hypertension, hyperthyroidism, seizures, arrhythmias, or sensitivity to sympathomimetic amines will be excluded from the BDR assessment.
boolean
C3166112 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
C0020538 (UMLS CUI [1,3])
C0020550 (UMLS CUI [1,4])
C0036572 (UMLS CUI [1,5])
C0003811 (UMLS CUI [1,6])
C0020517 (UMLS CUI [1,7])
C0002509 (UMLS CUI [1,8])
Elig.phs001347.v3.p2.21
Item
Any infant with hypersensitivity to any of components of albuterol sulfate will be excluded from the BDR assessment. An infant or child with such history may remain eligible for the remainder of the study if they qualify by other inclusion and exclusion criteria.
boolean
C0020517 (UMLS CUI [1,1])
C0543495 (UMLS CUI [1,2])
C2828389 (UMLS CUI [1,3])
C3166112 (UMLS CUI [1,4])
C1302261 (UMLS CUI [2,1])
C0020517 (UMLS CUI [2,2])
C0262926 (UMLS CUI [2,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial